Arrowstreet Capital’s Black Diamond Therapeutics BDTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BDTX
Arrowstreet Capital's BDTX Position: Q3 2026 in Review
Arrowstreet Capital sold out of Black Diamond Therapeutics (BDTX) in Q3 2026, closing a stake of 265,562 shares — an estimated $491K sold.
Arrowstreet Capital first reported a position in BDTX in Q2 2025 and held it in 5 quarters. The position peaked at $3.4M in Q3 2025. 110 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.
- Arrowstreet Capital reported no remaining Black Diamond Therapeutics position as of Q3 2026 after selling out during the quarter.
- Arrowstreet Capital sold 265,562 Black Diamond Therapeutics shares in Q3 2026, an estimated $491K.
- Arrowstreet Capital first reported a position in Black Diamond Therapeutics in Q2 2025 and held it in 5 quarters.
- Arrowstreet Capital's Black Diamond Therapeutics position peaked at $3.4M in Q3 2025.
- 110 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.
Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.